Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright

Key Points

• Altimmune's stock received a "buy" rating from HC Wainwright, with a price target of $12.00, suggesting a potential upside of 200% from its current price.
• Analysts have mixed opinions on Altimmune, with five rating it as a buy, while others, including Goldman Sachs, have issued lower ratings, such as a "strong sell."
• Altimmune reported earnings of ($0.27) per share, exceeding analyst expectations, despite a significant negative net margin and continued operational challenges.

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright's target price would suggest a potential upside of 200.00% from the stock's current price.

A number of other brokerages have also commented on ALT. The Goldman Sachs Group upgraded shares of Altimmune to a "strong sell" rating in a research note on Thursday, July 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Altimmune in a research note on Wednesday. William Blair reiterated a "market perform" rating on shares of Altimmune in a research note on Friday, June 27th. JMP Securities decreased their price target on shares of Altimmune from $25.00 to $15.00 and set a "market outperform" rating on the stock in a research note on Thursday, July 10th. Finally, Wall Street Zen upgraded shares of Altimmune from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $17.40.

Altimmune Trading Up 1.8%

Shares of NASDAQ:ALT opened at $4.00 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 20.44 and a quick ratio of 20.44. The company's 50-day moving average price is $3.71 and its two-hundred day moving average price is $4.63. The stock has a market capitalization of $353.03 million, a PE ratio of -3.39 and a beta of 0.07. Altimmune has a one year low of $2.90 and a one year high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.05. The company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. On average, equities analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in Altimmune by 1.2% in the 1st quarter. Bank of New York Mellon Corp now owns 189,000 shares of the company's stock valued at $945,000 after purchasing an additional 2,162 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Altimmune by 4.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock valued at $247,000 after purchasing an additional 2,241 shares during the last quarter. E Fund Management Co. Ltd. lifted its stake in Altimmune by 20.3% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company's stock valued at $67,000 after purchasing an additional 2,268 shares during the last quarter. MetLife Investment Management LLC lifted its stake in Altimmune by 5.4% in the 1st quarter. MetLife Investment Management LLC now owns 46,870 shares of the company's stock valued at $234,000 after purchasing an additional 2,396 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company's stock valued at $108,000 after purchasing an additional 2,748 shares during the last quarter. Institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.